Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
暂无分享,去创建一个
Larry Norton | C. Hudis | L. Norton | M. Theodoulou | T. Traina | K. Tan | S. Patil | Sujata Patil | Clifford Hudis | Tiffany A Traina | Maria Theodoulou | Kimberly Feigin | K Lee Tan | Charles Edwards | Ute Dugan | K. Feigin | U. Dugan | C. Edwards | K. Tan
[1] E. Van Cutsem,et al. Tolerability of fluoropyrimidines appears to differ by region. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[3] D. Berry,et al. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG , 2005 .
[4] Larry Norton,et al. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. , 2005, The oncologist.
[5] G. Rosner,et al. Prospective Evaluation of Body Surface Area as a Determinant of Paclitaxel Pharmacokinetics and Pharmacodynamics in Women with Solid Tumors , 2004, Clinical Cancer Research.
[6] J. Lokich. Capecitabine: Fixed Daily Dose and Continuous (Noncyclic) Dosing Schedule , 2004, Cancer investigation.
[7] Mark J. Ratain,et al. Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing , 2001, Investigational New Drugs.
[8] A. Schindler,et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Matthay,et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Scheithauer,et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] L. Grochow,et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. , 2002, Journal of the National Cancer Institute.
[13] Antonius A. Miller. Body surface area in dosing anticancer agents: scratch the surface! , 2002, Journal of the National Cancer Institute.
[14] W. Scheithauer,et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Ratain,et al. Update on pharmacogenetics in cancer chemotherapy. , 2002, European journal of cancer.
[16] Mary V. Relling,et al. Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.
[17] A. Buzdar,et al. Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.
[18] H. Burger,et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] F. D. De Braud,et al. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. , 2001, Trends in pharmacological sciences.
[20] W. Evans,et al. Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.
[21] H. Burger,et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Reigner,et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Gurney,et al. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Spratt,et al. Mammographic assessment of human breast cancer growth and duration , 1993 .
[27] J S Spratt,et al. Decelerating growth and human breast cancer , 1993, Cancer.
[28] L. Norton,et al. The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.
[29] A. J. Valleron,et al. A simulation model of the natural history of human breast cancer. , 1985, British Journal of Cancer.
[30] M. Retsky,et al. A stochastic numerical model of breast cancer growth that simulates clinical data. , 1984, Cancer research.
[31] L. Norton,et al. Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.
[32] L. Norton,et al. Growth curve of an experimental solid tumor following radiotherapy. , 1977, Journal of the National Cancer Institute.
[33] L. Norton,et al. Predicting the course of Gompertzian growth , 1976, Nature.
[34] H. Skipper,et al. Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.